In Denmark, researchers found that the risk of atypia, atypia+, and cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) were significantly reduced among women who received the vaccine.
Two doses of quadrivalent human papillomavirus (HPV) vaccine protects against genital warts nearly as well as the standard 3-dose schedule, according to new study findings.
Women who take aspirin daily may reduce their risk of ovarian cancer by 20%, new research has found. However, this preventive strategy isn't ready for prime time; additional study is needed before clinical recommendations can be made.
The rationale for annual mammography in women aged 40 to 59 years needs to be reassessed in countries where adjuvant therapy for breast cancer is available.
New research, led by Connie Trimble, MD, shows that vaccine treatments for women with high-grade cervical dysplasia can trigger an immune response that may induce some lesions to resolve.
New evidence reveals that there may be a benefit to continuing cervical cancer screening beyond age 65 years.
Women whose cervical cancer screening ceased between ages 50 and 64 years were 6 times more likely than women who were screened to have cervical cancer from ages 65 to 83 years.
Conservative surgery for early-stage vulvar cancer had little to no long-term effect on a woman’s sexuality or body image, a small study found.
Diagnosis and treatment of high-grade cervical dysplasia substantially increases the risk of cervical or vaginal cancer at or after age 60 years, a study finds.
A simple blood test using plasma thermogram could serve as an effective new indicator for detecting cervical cancer, including assessment of the cancer’s stage.